<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956498</url>
  </required_header>
  <id_info>
    <org_study_id>19 GENF 02</org_study_id>
    <nct_id>NCT03956498</nct_id>
  </id_info>
  <brief_title>Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy</brief_title>
  <acronym>FEMINICOL</acronym>
  <official_title>Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric study evaluating the impact of a nurse-led sexological follow-up on
      sexual function in patients with cervix or vaginal cancer treated by radiotherapy and
      brachytherapy.

      The study procedure will consist of nurse-led sexological consultations, beginning before
      brachytherapy and until 2 months after brachytherapy.

      Evolution of female sexual function and vaginal symptoms will be done through clinical
      examinations and completion of quality of life and female sexual function questionnaires
      during radiation oncologist consultation and/or nurse-led sexological consultations until one
      year after end of brachytherapy.

      Study participation of each patient will be 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Female Sexual Function Index score (evolution between inclusion and 1 year after brachytherapy) assessed using FSFI (Female Sexual Function Index) Questionnaire</measure>
    <time_frame>12 months for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed using QLQ-C30 questionnaire (Quality of Life Questionnaire-Core 30)</measure>
    <time_frame>12 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life specific for cervix cancer assessed using QLQ-CX24 questionnaire (Quality-of-Life questionnaire cervical cancer module)</measure>
    <time_frame>12 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal symptoms assessed using NCI-CTCAE version 5 (National Cancer Institute Common Toxicity Criteria for Adverse Events)</measure>
    <time_frame>12 months for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Cervix Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with cervix or vaginal cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy</intervention_name>
    <description>Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.
Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24.</description>
    <arm_group_label>Patients with cervix or vaginal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years or older

          2. Woman diagnosed with cervix or vaginal cancer, for whom a treatment by radiotherapy
             and brachytherapy has been decided

          3. Patient receiving for the first time an utero-vaginal or vaginal brachytherapy at
             &quot;Institut Universitaire du Cancer de Toulouse - Oncopole&quot;

          4. Easter Cooperative Oncology Group (ECOG) Performance Status â‰¤ 2

          5. All patients are eligible, regardless of their relationship status (in couple or not),
             their sexual orientation, and their hormonal status

          6. Patient willing to give informed consent before the study and before performing any
             study-related procedures

          7. Patient affiliated to a Social Health Insurance in France

        Exclusion Criteria:

          1. Patient not understanding the French language

          2. Patient for whom surgical treatment and brachytherapy has been decided

          3. Any psychological, familial, sociological or geographical condition that potentially
             hampers compliance with the study protocol and follow-up after treatment
             discontinuation schedule

          4. Patient who has forfeited his/her freedom by administrative or legal award or who is
             under legal protection (curatorship and guardianship, protection of justice
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne DUCASSOU</last_name>
    <phone>05 31 15 54 15</phone>
    <email>ducassou.anne@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josiane MENARD</last_name>
    <phone>05 31 15 51 36</phone>
    <email>menard.josiane@iuct-oncopole.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DUCASSOU</last_name>
      <phone>05 31 15 54 15</phone>
      <email>ducassou.anne@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervix Cancer</keyword>
  <keyword>Vaginal Cancer</keyword>
  <keyword>Sexual function</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginal Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

